Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Eloxatin

EISAI

Eisai’s Lenvima gets FDA priority review for kidney cancer

The oncology treatment could now be approved in the US before the summer

- PMLiVE

Merck & Co buys IOmet to boost immuno-oncology tech

Reports suggest it paid up to £280m for the Scottish biopharma company

- PMLiVE

An open letter to international brand teams

Abottom-up perspective on the development of international brands and campaigns

- PMLiVE

National Audit Office agrees CDF is ‘unsustainable’

Says a replacement for the CDF is urgently needed

- PMLiVE

Pharma perspectives: communications creativity (part 2)

David Higgins from Sudler & Hennessey Group on what it means to be creative in healthcare communications

- PMLiVE

Pharma perspectives: communications creativity (part 1)

AstraZeneca business unit director Samuel Hollis on what healthcare communications creativity means to him

- PMLiVE

Bedrock Healthcare Communications hires five

New starters include Sam Simpson and Francesca Worthington

- PMLiVE

Cube Creative moves offices and expands team

Manchester agency appoints Will Stone and Gemma Beharry

- PMLiVE

Why pharma needs to fall in love with creativity

As Cannes plays host to Lions Health, Shaheed Peera looks beyond default 'creative' settings

ASCO 2015: What you missed in Chicago

Blue Latitude sent two of our consultants to Chicago to attend ASCO 2015, a key annual meeting for oncology specialists that brings over 30,000 delegates together to talk about innovations...

Blue Latitude Health

- PMLiVE

Amgen and Merck to expand cancer collaboration

Firms to test Keytruda in combination for cancers inside the head and neck

- PMLiVE

Rise in cancer therapy costs ‘unsustainable’ says oncologist

Leonard Saltz made the claims in his keynote presentation at ASCO

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links